Restin protein expression in non‐small cell lung cancer

Background Restin is a member of the melanoma‐associated antigen (MAGE) superfamily. Its expression has been reported to be up‐ or downregulated in cancer. Preclinical data suggest it is a tumor suppressor. In this study, we aimed to evaluate restin expression and prognostic value in non‐small cell lung cancer (NSCLC). Methods Restin expression was analyzed by immunohistochemistry in three tissue microarrays consisting of formalin‐fixed/paraffin‐embedded NSCLC specimens from 113 patients, represented in triplicate. Restin staining H‐score was the result of the staining intensity (0‐no, 1‐weak, 2‐moderate, and 3‐strong) multiplied by the percentage of stained tumor cells; it was defined as low if 1–100, moderate if 101–200, and strong if 201–300. Haverage‐score was the average H‐score in the triplicate. Restin Haverage‐scores were tested for correlations with clinical and pathological characteristics and patient outcome. Results Restin expression was localized to the cytoplasm, with nuclear enhancement, of 112/113 (99.1%) NSCLCs. Restin Haverage‐scores were 0 in 1/113 (0.88%), low in 15/113 (13.3%), moderate in 48/113 (42.5%), and strong in 49/113 (43.4%) NSCLCs. Restin Haverage‐scores did not correlate with NSCLC histological subtype, disease stage, recurrence/progression‐free, or overall survival. Conclusion Restin is moderately to strongly expressed in the majority of NSCLC tumors but its expression has no prognostic value in patients with NSCLC. Restin is a member of the melanoma‐associated‐antigen (MAGE) superfamily. Its expression has been reported to be dysregulated in cancer. Preclinical data suggest its role as a tumor suppressor. We aimed to evaluate the expression of restin and its prognostic value in non‐small cell lung cancer (NSCLC). We found that restin is moderately to strongly expressed in the majority (85.9%) of NSCLC tumors but its expression evaluated by immunohistochemistry has no prognostic value in patients with NSCLC.